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Background: Placental growth factor [PlGF) is a cardiovascular (CV) risk marker, which is related to left ventricle
hypertrophy (LVH) in animal models. Currently there are no data available regarding the possible relationship of
PlGF and the development of LVH or diastolic dysfunction in patients with chronic kidney disease (CKD) and the
relationship of PlGF to other CV risk factors in CKD patients. The aim of our study was to determine the possible
association of PlGF and several other CV risk markers to echocardiographic parameters in CKD population.
Methods: We prospectively examined selected laboratory (PlGF, fibroblast growth factor-23 -FGF23, vitamin D,
parathyroid hormone, extracellular newly identified RAGE-binding protein - EN-RAGE, B-type natriuretic peptide -
BNP) and echocardiographic parameters in 62 patients with CKD 2–4. Mean follow-up was 36 ±10 months.
Laboratory and echocardiographic data were collected 2–3 times, at the shortest interval of 12 months apart.
Multivariate regression analysis was used to detect independent correlations of variables.
Results: Increased left ventricular mass index (LVMI, g/m2.7) was found in 29% patients with CKD 2–4, left
ventricular (LV) diastolic dysfunction was detected in 74.1% patients (impaired LV relaxation in 43.5% patients and
pseudonormal pattern in 30.6% patients). After 36 ± 10 months increased LVMI was found in 37.1% patients with
CKD 2–4, LV diastolic dysfunction was detected in 75.8% patients (impaired LV relaxation in 43.5% patients and
pseudonormal pattern in 32.3% patients). Following independent correlations were found: LVMI was related to PlGF,
cholesterol, BNP, systolic blood pressure and serum creatinine. EN-RAGE correlated positively with left atrial
diameter and inversely with E/A ratio. During the follow-up we found a significant increase in LVMI and left atrial
diameter, whereas a significant decrease in LVEF was noted.
Conclusion: According to our data, PlGF is independently related to increased LV mass in CKD, whereas EN-RAGE is
more likely related to diastolic dysfunction in this population.
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Cardiovascular risk in patients with chronic kidney disease
is increased in early stages of renal insufficiency and rises
with its progression. Traditional as well as specific CKD-
related risk factors lead to vascular calcification, left
ventricular hypertrophy (LVH) and myocardial fibrosis
[1-3]. In CKD patients, LVH is a common condition ori-
ginating in early CKD stages and its prevalence progresses
with declining renal function [4]. LVH may develop as a
compensatory mechanism to volume and pressure over-
load, but finally it contributes to the unfavourable outcome.
LVH in CKD is typically accompanied by collagen accumu-
lation, arteriolar wall thickening, calcification, and capillary
rarefaction, reduction in the number of cardiomyocytes and
hypertrophy. These mechanisms accelerate the onset of
systolic and diastolic dysfunction of the left ventricle. Left
ventricular (LV) diastolic dysfunction is an abnormality of
relaxation, filling or distensibility of the left ventricle that
portends a poor prognosis regardless of any associated
systolic dysfunction [5]. Three types of LV diastolic dys-
function involve: 1. impaired relaxation (grade I) 2. pseudo-
normalization (grade II) and 3.restrictive filling (grade III).
A number of pathways possibly responsible for the
high CV risk in CKD are currently being studied. These
mechanisms include hypertension, hyperactivity of the
renin-angiotensin-aldosterone system, anaemia, sodium
and volume retention, endothelial dysfunction, mineral
and vitamin D disorders, micro-inflammation and oxi-
dative stress [3]. These pathways are under constant
research, including investigation of biomarkers possibly
linking CKD to CV pathology, such as placental growth
factor (PlGF), extracellular newly identified RAGE-
binding protein (EN-RAGE), metalloproteinases, fibro-
blast growth factor 23 (FGF23), 25OHvitaminD and
parathyroid hormone (PTH).
One of the above mentioned biomarkers - Placental
growth factor (PlGF) - is a 149 aminoacid heterodimer,
expressed in human placenta, heart, thyroid gland, lung
and skeletal muscle. PlGF is a member of the pro-
proliferative vascular endothelial growth factor family
and a pro-atherogenic cytokine which stimulates angio-
genesis in ischemic tissues. It is up-regulated in athero-
sclerotic lesions, stimulates vascular smooth muscle
growth and up-regulates production of tumour necrosis
factor (TNF). PIGF is a biomarker of vascular inflamma-
tion and CV risk [6]. In animal models, PlGF is related
to LV hypertrophy [7,8], however little is known about
the relation of PlGF to LVH in human population.
Another pro-atherogenic molecule, Pregnancy associated
protein (PAPP-A), belongs to the family of metallo-
proteinases (MMPs). It has been found in plasma, vascu-
lar smooth muscle cells and in atherosclerotic plaques.
High plasma levels of PAPP-A have been found in dialy-
sis patients [9]. Products of non-enzymatic glycation andoxidation of proteins and lipids, advanced glycation-end
products (AGEs), accumulate in CKD and they play a role
in the development of atherosclerosis. Binding of AGEs to
their receptor (RAGE) activates the pro-inflammatory
transcription factor NF-kB. EN-RAGE is an extracellular
ligand for RAGE which has been found to exert pro-
inflammatory effects [10]. Impaired calcium-phosphate
metabolism is another factor contributing to the high CV
morbidity and mortality in CKD [11] and vitamin D defi-
ciency resulting in increased plasma FGF23 levels in CKD
patients might directly cause vascular calcification,
increased arterial stiffness, endothelial dysfunction and LV
hypertrophy [12].
No data exist so far, about the possible relationship of
PlGF and the development of LVH or diastolic dysfunc-
tion in CKD patients and the possible relationship of PlGF
and other CV risk markers. Little is known about echocar-
diographic changes in patients with earlier CKD stages.
Therefore, we aimed to study the possible association of
PlGF and several other pro-atherogenic molecules or CV
risk markers with echocardiographic parameters in CKD
2–4 patients.
Methods
Between December 2004 and May 2009, 76 subjects with
mild to moderate renal insufficiency (CKD 2–4) were
consecutively recruited in the Outpatient unit of the
Department of Nephrology (General University Hospital,
Charles University, Prague). These subjects were follo-
wed during a mean period of 36 ± 10 months. We
prospectively examined selected laboratory and echo-
cardiographic characteristics of these subjects. Data were
collected 2–3 times, at the shortest interval of 12
months apart. During the follow up period 8 patients
died and 6 withdrew the informed consent. Final data
analysis was performed only in 62 patients who com-
pleted the whole follow up period. Estimated glomerular
filtration rate (eGFR) was calculated by MDRD formula.
CKD was defined as a reduction in eGFR below 1 ml/s/
1.73 m2.
Clinical and demographic characteristics of the group
are presented in Table 1. Etiology of CKD was: ischemic
nephropathy (21%), IgA nephritis (15%), chronic pyelo-
nephritis (13%), hypertensive nephropathy (11%), diabetic
nephropathy (10%), ANCA associated vasculitis (5%),
lupus nephritis (5%), and other (20%). About 92% of
patients received ACE inhibitors and/or AR blockers, 13%
were substituted with calcium, 44% received calcitriol and
61% were on statin therapy.
History of CV disease was taken from medical records
of each patient, comprising coronary heart disease, per-
ipheral arterial obstructive disease and/or cerebrovascu-
lar disease. History of CV disease was noted in 31
patients (50%). No patient had symptoms of severe heart
Table 1 Baseline clinical and demographic characteristics
of the study group
Variable ± SD
Number of patients 62
Age (years) 62 ± 15
Men 37
Women 25
BMI (kg/m2) 26,9 ± 3,9
Hypertension % 88,7
Mean systolic BP (mm Hg) 133 ± 16
Mean diastolic BP (mm Hg) 80 ± 7
Number of antihypertensive drugs 3 ± 2
History of CVD % 50
DM % 21
Abbreviations: BMI Body mass index, BP blood pressure, CVD cardiovascular
disease, DM Diabetes mellitus.
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cant valvular defect.
Blood samples
Fasting venous blood samples from each patient were
collected. All samples were centrifuged for 10 min
at 1.450 g (4°C). Sera were stored at −80°C until
analysis.
Biochemical analysis
FGF23 (C terminal fragment) was measured with ELISA
kit according to the manufacturer protocol (Immune
topics, San Clements, CA, USA). PAPP-A was assessed
immunochemically with the TRACE (Time Resolved
Amplified Cryptate Emission) technology based on non-
radiating energy transfer (commercial kit KRYPTOR-
PAPP-A, Brahms, Germany). MMP-2 and PlGF were
measured with ELISA, Standard kits Quantikine, RD
systems, Minneapolis, MN, USA. Biointact parathyroid
hormone levels were analysed with ECLIA method
(ROCHE, analyser MODULAR SWA). Brain natriuretic
peptide (BNP) and troponin I (cTnI) were measured by
chemiluminiscence methods (UniCel DxC 880i - Beckman
Coulter analyzer). sRAGE and EN-RAGE were measured
using standard ELISA kits according to the manufacturers’
protocols: sRAGE (Quantikine, RD Systems, Minneapolis,
MN, USA, www.rndsystems.com), EN-RAGE (CirculexTM,
CycLex Co. Ltd., Nagano, Japan, www.cyclex.xo.jp). Routine
biochemical parameters were assessed by standard labora-
tory methods.
Echocardiography was carried out approximately 2
hours after blood sampling.
Complete two-dimensional M-mode and Doppler
studies were performed via standard approaches, usingVivid 7 (GE Medical system, Waukesha, Winconsin). M-
mode examination was performed according to American
Society of Echocardiography guidelines [13] LV mass was
determined using standard formula, as follows: Left
ventricular mass = 0.8 × (1.04 × (LVEDD+ PWTd +
SWTd)3 – (LVEDD)3) + 0.6 [13]. The values were indexed
by the patient’s height2.7, thus obtaining left ventricular
mass index (LVMI). LV hypertrophy was defined as LV
mass index >46.7 g/m2.7 in women or 49.2 g/m2.7 in men.
Relative wall thickness, calculated as 2-times posterior
wall thickness divided by LV internal diastolic dimension,
was used to characterise LV geometry into following
categories: normal (≤ 0.42 and normal LVM), concentric
remodeling (normal LVMI but RWT > 0.42), concentric
hypertrophy (− increased LVMI and RWT> 0.42), and
eccentric hypertrophy (− increased LVMI and RWT ≤ 0.42).
LV volumes, comprising end-diastolic (LVEDV) and end-
systolic volume (LVESV) were estimated using modified
Simpson method, and used to calculate LV ejection frac-
tion. Doppler characteristics of LV filling and diastolic
function were assessed by using transmitral flow pattern
along with pulmonary venous inflow parameters. In most
patients we recorded mitral annular velocities. According
to the current recommendations the filling was catego-
rized as normal, impaired relaxation, pseudonormal and
restrictive [14,15]. Left atrial diameter (LAD) was indexed
to body surface area, obtaining the parameter LAD/BSA
(mm/m2). In patients with mild diastolic dysfunction, the
mitral E/A ratio is < 0.8, deceleration time of inflow of the
E wave, (DT) is > 200 ms. In patients with moderate
diastolic dysfunction (grade II), the mitral E/A ratio is 0.8
to 1.5 (pseudonormal) and decreases by ≥ 50% during the
Valsalva maneuver. With severe diastolic dysfunction
(grade III), restrictive LV filling occurs with an E/A
ratio ≥ 2, DT < 160 ms [14,15].
The study was approved by the Ethical Committee of
General University Hospital in Prague, reference num-
ber: 50/08. A written informed consent was obtained
from all participants.
Statistics
The results of biochemical parameters are expressed as
mean ± SD, in case of non-normal data distribution as
medians and interquartile ranges. Comparisons were
conducted with paired sample t tests for normally
distributed continuous variables and Wilcoxon test for
non-normal distributions. Variables with non-normal
distributions were ln- transformed where appropriate.
Association among analyzed parameters was assessed by
Pearson’s correlation coefficient. Subsequently, linear
regression analysis for determinants of echocardiographic
parameters influential variables was performed. All
variables significantly associated with echocardiographic
characteristics were included in the multiple regression
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25OH vitamin D, BNP, FGF23, serum creatinine, EN-
RAGE, PTH, PAPP, Pi, sRAGE, serum TAG, MMP2).
Qualitative variables, such as tobacco smoking, history
of CV disease, use of ACE inhibitors, were analysed
using the Kruskal-Wallis test. Chi-Squared Test for
Trend was used to compare baseline and final echo-
cardiographic findings in the subject group (Table 2).
Results were considered as statistically significant at
p < 0.05. All analyses were performed using MedCalc
9.3 (MedCalc Software Comp. Mariakerke, Belgium).Table 2 Echocardiographic characteristics (%) of the
study group (n = 62)
Baseline After 36
months + − 10
p value chi square
test for trend
LV mass index (g/m2.7)
















normal 88,7 87,1 p = 0.68 NS
decreased 11,3 12,9
LAD (cm/m2)





25,8 24,2 p = 0.96 NS





below 0.8 46,8 48,4 p = 0,06 NS
0-8-1.5 50,0 40,3
above 2 3,2 11,3
DTE-MI (ms)
above 200 38,7 62,9 p < 0.01
160-200 37,1 27,4
under 160 24,2 9,7
Abbreviations: E/A ratio Ratio between early (E) and late (atrial - A) ventricular
filling velocit, DTE-MI Decelaration Time on Mitral Valve, LAD left atrial
diameter, LV left ventricular.Results
1. Baseline echocardiographic parameters of the
study group (Table 2).
Increased LV mass was noted in 29% patients. We
identified 56.5% subjects with normal LV geometry,
12.9% subjects with concentric remodelling, 9.7%
subjects with concentric hypertrophy and 21%
subjects with eccentric hypertrophy. Normal LV
diastolic function was found in 25.8% patients,
impaired LV relaxation in 43.5% patients and
pseudonormal pattern in 30.6% patients. No one
met the criteria of restrictive pattern of LV
diastolic filling.
2. Echocardiographic parameters of the study group
after 36 ± 10 months (Table 2).
Increased LV mass was noted in 37.1% patients. We
identified 43.5% subjects with normal LV geometry,
21% subjects with concentric remodelling, 9.7%
subjects with concentric hypertrophy and 25.6%
subjects with eccentric hypertrophy. Normal LV
diastolic function was found in 24.2% patients,
impaired LV relaxation in 43.5% patients and
pseudonormal pattern in 32.3% patients. No one
met the criteria of restrictive pattern of LV
diastolic filling.
3. Independent correlations of echocardiographic
parameters, laboratory markers and blood
pressure (Table 3, Figure 1).
LV mass index was positively related to PlGF, BNP,
systolic BP and serum creatinine. BNP positively
correlated also with left atrial diameter. EN-RAGE
was positively related to left atrial diameter and
inversely to E/A. PTH inversely correlated with
LVEF. No independent correlations were found
between echocardiographic parameters and
haemoglobin, PAPP-A, FGF23 or vitamin D levels.
PlGF was not related to blood pressure.
4. Impact of renal function on laboratory and
echocardiographic parameters and their changes
during the follow-up period (multiple regression)
(Table 4, Figure 2).
eGFR was positively related to E/A ratio and
inversely related to LVMI and left atrial diameter.
During the follow-up, with the decline of eGFR, we
noted a significant increase in LVMI, left atrial
diameter, EN-RAGE, FGF23 and BNP, whereas a
decrease was observed in LVEF, serum albumin,
vitamin D and haemoglobin. No significant changes
in blood pressure were noted.
5. Laboratory parameters in patients with history of
CV disease.
History of CV disease was noted in 50% of patients.
These patients had higher LVMI (p < 0.02), serum
Table 3 Independent correlations of laboratory and echocardiographic parameters (stepwise multiple regression)
LVMI1 LVMI3 LAD 1 LAD 2 LAD 3 EF1 EF2 EF3 E/A 1 E/A 2 E/A 3
MDRD r = −0,31 r = −0,37 r = −0,25 r = −0,37 r = −0,41 - - - r = 0,54 r = 0,43 r = 0,40
p = 0,02 p < 0,01 p = 0,06 p < 0,02 p < 0,01 p < 0,0001 p < 0,01 p < 0,01
Serum Albumine r = −0,27 - - r = −0,33 r = −0,33 - - - - -
p < 0,05 p < 0,05 p = 0,02
PTH - - - - - - r = −0,47 - - - -
p < 0,01
EN-RAGE - - r = 0,35 - - r = −0,26 - - r = −0,34 - -
p < 0,01 p < 0,05 p = 0,01
PIGF - r = 0,31 - - r = 0,36 - - - - - -
- p < 0,02 p < 0,01
BNP r = 0,42 r = 0,51 r = 0,27 r = 0,30 r = 0,50 - - - - - -
p < 0,01 p < 0,001 p < 0,05 p = 0,08 p < 0,01
systolic BP - r = 0,31 - - - - - - - - -
p < 0,02
Legend: The 3 values for each parameter stand for serial echo exams at different time points (1: baseline assessment, 2: control 1 assessment 3: control 2
assessment). Only significant correlations are presented, independent correlations are highlighted.
Abbreviations: BNP brain natriuretic peptide, BP blood pressure, E/A Ratio between early (E) and late (atrial - A) ventricular filling velocity, EF left ventricular ejection
fraction, EN-RAGE Extracellular newly identified RAGE-binding protein, DT deceleration time on mitral valve, LAD left atrial diameter, LVMI left ventricle mass index,
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(p < 0.02) and PAPP-A (p < 0.05), whereas they had
lower 25OHvitamin D (p < 0.05) and serum albumin
levels (p < 0.01), compared to those free of such
history. Relation of PlGF to CV disease history was
of borderline significance (p = 0.05).
To sum up the results: During the follow-up period
(initially, resp. after 36 ± 10 months) we noted an
increased LVMI in 29%, resp. 37.1% of patients,
abnormal LV geometry in 43.5%, resp. 56.5% and
abnormal LV diastolic function in 74.1%, resp. 75.8
of subjects. However, these trends were not
significant. LVMI correlated with PlGF, BNP, systolic
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ure 1 Correlation of PlGF levels to LV mass index (g/m2.7)
0.31, p < 0.02. Based on final data. PlGF: placental growth factor,
left ventricle.EN-RAGE and eGFR. During the follow-up, with
declining eGFR we noted an increase in LVMI, left
atrial diameter, EN-RAGE, FGF23 and BNP, whereas
a decrease was observed in LVEF, serum albumin,
vitamin D and haemoglobin.Discussion
In the group of patients with mild to moderate CKD, we
noted a high prevalence of LV remodelling and increased
LV mass with rising frequency in more severe CKD. We
detected increased LVMI in 14% patients with CKD 2, in
21% with CKD 3 and in 48% patients in CKD 4 stages
(Figure 2, Table 2). Levin et al. have reported the prevalence
of LVH in 26.7% of patients with GFR > 50 mL/min, in
30.8% of those with GFR between 25 and 49 mL/min and
in 45.2% of patients with severe CKD (GFR <25 mL/min
[16], which is more or less in accordance with our findings.
High prevalence of increased LVMI in CKD has been
repeatedly described [16-18], but the studies are difficult
to compare due to different definitions of LVH, different
study populations and variations in blood pressure
control, including the use of ACE inhibitors and/or ARBs.
LV mass index in our study correlated independently
with systolic BP, BNP, serum creatinine and PlGF. The
relationship of BNP to LVMI and CV pathology has
already been described [19-21] and a correlation of
LVMI to BNP, CRP and troponin T has been reported in
CKD 3–4 stages [22]. However, in our present study we
failed to show a significant correlation of LVMI to tropo-
nin or CRP.
Table 4 Changes of laboratory and echocardiographic parameters during the follow-up period
Parameter Baseline After
18 months ± 5
After













eGFR (MDRD) (ml/s) 0.6 0.57 0.49 p < 0.01 p < 0.05 p < 0.01
(0.25-1.6) (0.25-1.3) (0.26-2.8)
Haemoglobin (g/l) 128.5 ± 20.0 128.8 ± 20.7 124.3 ± 18.8 p < 0.01 p < 0.01 NS
Serum Phosphate (mmol/l) 1.10 1.16 1.20 NS NS NS
(1.00-1.29) (1.00-1.45) (1.00-1.36)
Parathyroid hormone (pg/ml) 5.96 6.34 7.52 NS NS NS
(3.56-9.22) (4.56-11.98) (3.63-15.59)
25OH Vitamin D (ng/ml) 23.47 ±8.91 25.04 ±9.61 20.87 ±7.79 NS p < 0.01 p < 0.02
FGF23 (RU/ml) 89.6 100.1 127.0 p < 0.01 p < 0.05 p < 0.0001
(64.8-167.1) (73.0-228.8) (78.3-282.4)
PAPP-A (mIU/l) 8.3 8.7 9.3 NS NS NS
(7.0-10.2) (7.6-10.5) (7.5-12.6)
sRAGE (pg/ml) 976.3 919.1 1040.7 NS NS NS
(720.6-1495.2) (643.9-1336.3) (719.1-1375.1)
EN-RAGE (ng/ml) 160.5 255.2 269.8 p < 0.05 NS p < 0.001
(100.5-240.3) (164.6-297.0) (163.0-326.3)
PlGF (pg/ml) 10.80 11.05 12.5 p < 0.02 NS NS
(7.8-14.2) (8.5-15.6) (8.5-14.7)
MMP-2 (ng/ml) 214.5 ±50.6 206.5 ±39.2 221.9 ±61.6 NS NS NS
Troponin I (ng/ml) 0.01 0.01 0.01 NS NS NS
(0.01-0.01) (0.01-0.01) (0.01-0.01)
BNP (pg/ml) 30.0 57.0 77.0 p < 0.01 NS p < 0.0001
(15.0-91.0) (27.8-107.3) (40.0-195.0)
Left ventricle mass index (g/m2.7) 43.6 ± 14.6 45.3 ± 16.0 45.7 ± 13.4 NS NS p < 0.05
Left ventricle EF (%) 64.7 ± 7.8 64.5 ± 5.8 62.7 ± 8.0 p < 0.05 NS p < 0.05
Left atrial diameter (cm/m2) 2.14 ± 0.64 2.05 ± 0.55 2.19 ± 0.50 NS NS p < 0.01
E/A ratio 0.83 0.83 0.81 NS NS NS
(0.67 - 1.14) (0.69 - 0.98) (0.72-1.04)
Arithmetic mean ± SD or median (Interquartile Range).
Comparison: Paired samples t-test for normal distributions, resp. Wilcoxon test for skewed distrubutions.
Abbreviations: BNP brain natriuretic peptide, BSA body surface area, E/A ratio Ratio between early (E) and late (atrial - A) ventricular filling velocity eGFR: estimated
glomerular filtration rate, EN-RAGE Extracellular newly identified RAGE-binding protein, FGF23 fibroblast growth factor 23, MDRD modification of diet in renal
disease, MMP-2 matrix-metaloproteinase 2, PAPP-A pregnancy associated protein A, PlGF placental growth factor.
Peiskerová et al. BMC Nephrology 2013, 14:142 Page 6 of 9
http://www.biomedcentral.com/1471-2369/14/142In contrast, the correlation of PlGF to LV mass in
CKD patients has not been reported so far. In an animal
study [23], PlGF overexpressing mice exhibited a greater
cardiac hypertrophic response, an increase in capillary
density and in fibroblast content in the heart in response
to stress. Thus, PlGF overexpressing mice showed a type
of cardiac growth, which was protective against signs of
failure. Contrarily, PlGF(−/−) mice died of heart failure
within 1 week of pressure overload. PlGF probably
works through endothelial cells and fibroblasts, second-
arily stimulating the myocytes through paracrine factors,
such as interleukin-6 [24]. PlGF has been reported tostimulate angiogenesis in the infarction border [7], to pro-
mote atherosclerotic intimal thickening and macrophage
accumulation and has been associated with long-term
prediction of CHD [25,26]. In human atherosclerotic
lesions PlGF expression has been associated with plaque
inflammation, suggesting its role in plaque destabilization.
Delivery of anti-PlGF antibody delayed the progression of
atherosclerotic plaques to vulnerable lesions [24]. The
expression of PlGF in human vascular endothelial and
smooth muscle cells has been reported to be induced by
angiotensin II and aldosterone [8] and conversely, mine-






















Figure 2 LV mass index (g/m2.7) in different CKD stages. Based on baseline data. LV: left ventricle, CKD: chronic kidney disease.
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reported to be significantly higher in CKD 1–4 stage and
hemodialysis patients compared to controls [28]. In-
creased PlGF levels have been found in patients with CV
event history compared to those free of such history [28]
which is in accordance with our findings.
LV hypertrophy is a strong predictor of CV events and
of the risk of progression to dialysis [18]. Interestingly,
several studies in CKD patients have shown the lack of
correlation between blood pressure and LV mass [29],
suggesting that other neuro-humoral factors, promoting
myocardial fibrosis, might play a key role in the increase
of LV mass. In CKD patients, LV mass has been reported
to be independently related e.g. to albuminuria, FGF23
[29-31] and to CaxPO4 [32]. In a prospective study in
3879 CKD subjects, higher FGF23 levels were associated
to mortality risk [12]. FGF23 caused hypertrophy of
isolated rat cardiomyocytes and treatment with an FGF-
receptor blocker attenuated LVH. According to our data,
FGF-23 correlated with LVMI, however this relation did
not prove independent in multiple regression analysis. In
contrast, we noted an independent inverse correlation of
PTH levels with LVEF. Association of PTH with myocar-
dial hypertrophy, fibrosis and higher coronary lesion
score was described in animal model [33].
LV diastolic dysfunction has been observed already in
CKD 1–2 stages [15,33]. CKD severity was the most
independent predictor of elevated LV filling pressure
[34,35]. Our baseline data in CKD 2–4 show normal
diastolic function in 25.8% in of patients, impaired rela-
xation in 43.5%, and pseudonormal pattern in 30.6% of
subjects (Table 2).
We noted a positive correlation of EN-RAGE with left
atrial diameter and an inverse correlation with E/A. The
RAGE pathway could be a causal risk factor for LVHand coronary atherosclerosis. Recent data show that EN-
RAGE (also called S100A12) contributes to inflamma-
tion and atherosclerosis [36] and an early blockade of
RAGE by statins may prevent inflammation in athero-
sclerosis [37]. S100A12 levels have not been reported to
be elevated in CKD patients, but they have been shown
to be positively correlated with CRP and negatively
correlated with sRAGE [28]. An inverse relationship has
been described between sRAGE and LVMI in CKD
patients [38,39], but in the present study we failed to
note such a correlation.
During the follow-up period we noted a rising percent-
age of subjects with increased LVMI, abnormal LV
geometry, decreased LVEF and LV diastolic dysfunction
(Table 2), but this trend was not significant, probably
due to the time span limited to 36 ± 10 months.
Currently, the regression of LVH may be achieved
mainly by antihypertensive and anemia treatment
[16,40]. Of note, 48 week therapy with paricalcitol did
not alter LVMI or improve diastolic dysfunction in
patients with CKD (PRIMO study) [41]. To specifically
target LVH in the CKD population, we need to better
understand the molecular events that promote LVH
even in the absence of pressure or volume changes in
CKD. Randomized controlled trials are needed to find
whether LVH, cardiac fibrosis, and electrical instability
that plague patients with CKD can be prevented by
aggressive multifactorial therapy started early in CKD,
possibly including therapeutic lowering of PlGF, FGF23
or EN-RAGE levels. In this prospective observational
study we performed repeated laboratory assessment in a
close timely relation to echocardiographic measurements,
in order to analyse dynamic changes and correlations of
these parameters. We must call attention to some limita-
tions of the present study: due to a relatively high number
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number of subjects, we cannot exclude the possibility of
false positive findings. However, appropriate multiple
regression stepwise analyses (i.e. a multimarker approach)
to detect independent correlations of variables, were per-
formed. We did not consider appropriate to perform ROC
curves, as this analysis is considered meaningful in at least
100 observations [42]. Another limitation is the assess-
ment of the filling pattern only from transmitral flow.
However, normal pattern was distinguished from pseudo-
normal by experienced cardiologists taking into account
also pulmonary venous flow, left atrial dilatation and in
some patients also tissue Doppler imaging. We did not
systematically perform the mitral annulus excursion
velocity measurements using tissue Doppler, since it was
not routinely used in 2005, at the beginning of the study.
Conclusions
Our data describe for the first time an independent and
significant relationship of PlGF to increased LV mass in
mild to moderate CKD. EN-RAGE seems more likely
related to diastolic dysfunction in this population. We
report serial echocardiographic changes in CKD 2–4,
such as increased LV mass index and diastolic dysfunc-
tion progressing with time along with the declining renal
function. Further investigation is needed to demonstrate
which strategy is most efficient in preserving the cardiac
structure and function.
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